IC
IRD

Ikarian Capital’s Opus Genetics IRD Stock Holding History

Ikarian Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-124,021
Closed -$401K – 211
2022
Q1 		$401K Buy
124,021
+5,958
+5% +$20.4K 0.05% 142
2021
Q4 		$442K Hold
118,063
– – 0.07% 133
2021
Q3 		$608K Sell
118,063
-1,488
-1% -$6.86K 0.04% 178
2021
Q2 		$632K Hold
119,551
– – 0.05% 177
2021
Q1 		$693K Buy
+119,551
New +$1.11M 0.02% 249

Other funds holding IRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $192M AUM 23.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ikarian Capital's IRD Position: Q2 2022 in Review

Ikarian Capital sold out of Opus Genetics (IRD) in Q2 2022, closing a stake of 124,021 shares — an estimated $401K sold.

Ikarian Capital first reported a position in IRD in Q1 2021 and held it in 5 quarters. The position peaked at $693K in Q1 2021. 38 funds tracked by Wall St. Rank hold IRD as of Q2 2022.

  • Ikarian Capital reported no remaining Opus Genetics position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 124,021 Opus Genetics shares in Q2 2022, an estimated $401K.
  • Ikarian Capital first reported a position in Opus Genetics in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Opus Genetics position peaked at $693K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.